Compare GSK plc (GSK) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Koninklijke Philips NV — how do they compare? GSK plc trades at $52.38 (market cap $101.34B), while Koninklijke Philips NV trades at $27 (market cap $26.29B). The key difference: GSK plc is far larger — about 3.9× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| GSK | PHG | |
|---|---|---|
Market Cap | $101.34B | $26.29B |
Sector | Health | Health |
52-Week High | $61.18 | $32.91 |
52-Week Low | $36.20 | $24.38 |
Enterprise Value | $121.95B | $32.56B |
Dividend Yield | 3.49% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Royal Philips (PHG) trades at $26.06, down 4.68% today, with bearish technical signals but improving fundamentals. The company reported strong Q1 2026 earnings beat and maintains a 5.5% net income margin. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight innovation momentum. Cash flow remains positive at $403M for 2025, though debt-to-asset ratio increased to 25.44%.
PHG shows recovery potential with earnings growth and AI healthcare adoption, but faces execution risks and technical weakness. Analyst consensus leans Hold (59%) with no Sell ratings, suggesting cautious optimism. Key risks include competitive pressures and macroeconomic volatility affecting medical equipment demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
